`
`£,
`LUCENTIS
`R/'-.N I Bl:ZUM/\8
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date March 19, 2012
`Meeting Notes Date: March 29, 2012
`Author:
`Room: WSJ-340.3.09
`Dial-in:
`
`Team Members : ( ✓ = Present,* = part-time)
`
`Team Members : (✓ = Present,* = part-time)
`
`Executive Summary
`
`I
`I
`I
`
`I
`I
`I
`I
`I·
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`1 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`-I
`
`Pre•read
`none
`
`-
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`2of6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`1111
`I·
`
`-I
`
`I
`
`None
`
`None
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`3of6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`None
`
`-I
`
`I
`
`-I
`
`-I
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`4of6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`5of6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`------
`
`Action Plan
`
`Activit descri tion
`
`Code
`
`LF
`
`Lucentis PFS, CMC SubTeam Meeting Minutes, Meeting Date: March 19, 2012
`
`6of6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2074.006
`Regeneron v. Novartis, IPR2021-00816
`
`